Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Recipient : NRx Pharmaceuticals
Deal Size : $345.0 million
Deal Type : Collaboration
NRx Pharmaceuticals Announces $5 Million Milestone from Alvogen and Lotus Pharma
Details : The collaborations aim to support NRx for the development of NRX-101 (D-cycloserine) in the treatment of bipolar depression with suicidality.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $10.0 million
November 02, 2024
Lead Product(s) : Cycloserine,Lurasidone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Recipient : NRx Pharmaceuticals
Deal Size : $345.0 million
Deal Type : Collaboration
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : TWi Pharmaceuticals
Deal Size : $38.5 million
Deal Type : Acquisition
Bora Acquires Six US Brand Product Licenses, Rights
Details : Through the acquisition, Bora will utilize Almatica's generic pharmaceutical products, including Zestril (lisinopril), an oral tablet used for treating hypertension, for commercialization purposes.
Product Name : Zestril
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 18, 2023
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : TWi Pharmaceuticals
Deal Size : $38.5 million
Deal Type : Acquisition
Lead Product(s) : Rifaximin
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XIFAXAN (rifaximin) is a 2 week prescription treatment that provided up to 6 months of relief from IBS-D symptoms of abdominal pain and diarrhea in a clinical trial.
Product Name : Xifaxan-Generic
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 08, 2022
Lead Product(s) : Rifaximin
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifaximin
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin
Details : XIFAXAN (rifaximin) 200 mg tablets are indicated for travelers diarrhea. XIFAXAN (rifaximin) 550 mg tablets are indicated for reduction in risk of overt hepatic encephalopathy recurrence in adults and for the treatment of irritable bowel syndrome with di...
Product Name : Xifaxan-Generic
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 09, 2022
Lead Product(s) : Rifaximin
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Phentermine
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase IV Study of Qsymia in Obese Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 18, 2022
Lead Product(s) : Phentermine
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buprenorphine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : BioDelivery Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BELBUCA® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Product Name : Belbuca
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 20, 2021
Lead Product(s) : Buprenorphine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : BioDelivery Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : AZTIQ PHARMA
Deal Size : $350.0 million
Deal Type : Acquisition
Aztiq Buys 17% Stake in Alvogen US
Details : Zestril (lisinopril) belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily. Zestril is used to treat high blood pressure (hypertension) in adults and children who are at least 6 years old.
Product Name : Zestril
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 30, 2021
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : AZTIQ PHARMA
Deal Size : $350.0 million
Deal Type : Acquisition
Lead Product(s) : Quetiapine Hemifumarate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Recipient : Luye Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : Luye Pharma granted Alvogen Korea, Zuellig Pharma and DKSH exclusive distribution and marketing rights to Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in their respective regions of South Korea, Hon...
Product Name : Seroquel
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 06, 2020
Lead Product(s) : Quetiapine Hemifumarate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Luye Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : AK-R215
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AK-R215 Pharmacokinetic Study Phase I
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 25, 2017
Lead Product(s) : AK-R215
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DP-R213
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
DP-R213 Phase 1 Pharmacokinetics Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 05, 2017
Lead Product(s) : DP-R213
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable